COMMUNIQUÉS West-GlobeNewswire

DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities
09/02/2026
Châtillon, France, le 9 février (22 :30 CET) 2026 DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – [...]
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
09/02/2026
Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ [...]
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
09/02/2026
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
09/02/2026
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business [...]
Synfini Introduces Integrated Microscale Purification, Delivering Assay-Ready Compounds in Hours Instead of Days
09/02/2026
New Capability Collapses the Design-Make-Test-Analyze (DMTA) Cycle, Accelerating Real SAR Learning with High-purity Compounds for Direct-to-Biology Screening MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Synfini [...]
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
09/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL [...]
AB Science annonce que la Food and Drug Administration (FDA) américaine a accordé le statut de Minor Use in Major Species (MUMS) au Masivet® dans le traitement des tumeurs mastocytaires chez le chien
09/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE QUE LA FDA A ACCORDÉ LE STATUT DE “MINOR USE IN MAJOR SPECIES” (MUMS) AU MASIVET DANS LE TRAITEMENT DES TUMEURS MASTOCYTAIRES CHEZ LE CHIEN AB SCIENCE PRÉSENTE LES PERSPECTIVES DE [...]
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/02/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/02/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
ProQR Announces Planned Changes to Board Composition
09/02/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Carterra Launches Industry’s First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization
09/02/2026
Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional and AI-based drug discovery Enables primary screening with high-resolution binding First order and shipment slated [...]
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
09/02/2026
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday [...]
QuantX Biosciences Closes Oversubscribed $85M Series B Financing
09/02/2026
Round co-led by LAV and Sanofi Ventures PRINCETON, N.J. and SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- QuantX Biosciences, Inc. , a computationally driven drug discovery and development company using advanced modeling [...]
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
09/02/2026
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for [...]
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
09/02/2026
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota, Fla [...]
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
09/02/2026
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company [...]
Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
09/02/2026
SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium [...]
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
09/02/2026
Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz ® vs. vehicle gel (p<0.0003) Actinic keratosis (AK) is the most common skin condition diagnosed by US [...]
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
09/02/2026
New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 [...]

Pages